Insulin Growth Factor Binding Protein-6 and the Liver

Area of Science:

• Liver biology and disease
• Endocrinology
• Molecular signaling

Background:

• The insulin-like growth factor (IGF) axis is crucial for liver function, but individual IGF-binding proteins (IGFBPs) roles are unclear.
• IGFBP-6, an IGF-II-preferring binding protein, influences IGF bioavailability and signaling, with independent actions.

Purpose of the Study:

• To synthesize current evidence on IGFBP-6 in liver biology and disease.
• To evaluate its roles in hepatic development, homeostasis, injury, and cancer.
• To assess its translational potential for diagnosis and therapy.

Main Methods:

• Review of experimental and clinical data on IGFBP-6 expression, regulation, and function.
• Analysis of IGFBP-6 involvement in canonical IGF signaling pathways (PI3K-AKT, RAS-MAPK).
• Examination of IGFBP-6 links to liver conditions like steatosis, inflammation, fibrosis, and cancers (HCC, cholangiocarcinoma).

Main Results:

• IGFBP-6 expression and processing vary with liver development, homeostasis, and injury.
• It modulates IGF-II/IGF1R signaling and downstream pathways.
• IGFBP-6 is implicated in steatosis, inflammation, fibrogenesis, and liver cancers, showing both tumor-suppressive and pro-migratory effects.
• Potential crosstalk with hypoxia, Wnt/β-catenin, TGF-β signaling, and the immune microenvironment.

Conclusions:

• IGFBP-6 is a nuanced regulator of liver pathophysiology.
• It holds promise as a biomarker for patient stratification and therapeutic targeting.
• Further research is needed for standardized measurement, cell-type-resolved profiling, and in vivo studies.